Alloplex Biotherapeutics, Inc. announced that it has received funding from new investors Daewoong pharmaceutical Co.,Ltd. and Hanall Biopharma Co.,Ltd on August 19, 2021.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
34,150 KRW | +3.96% | +8.24% | -22.91% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-22.91% | 1.26B | |
+46.68% | 765B | |
-6.14% | 354B | |
+20.17% | 331B | |
+8.84% | 299B | |
+18.94% | 248B | |
-1.72% | 219B | |
+10.99% | 216B | |
+5.37% | 164B | |
-2.74% | 162B |
- Stock Market
- Equities
- A009420 Stock
- News Hanall Biopharma Co., Ltd.
- Alloplex Biotherapeutics, Inc. announced that it has received $1 million in funding from Daewoong pharmaceutical Co.,Ltd, Hanall Biopharma Co.,Ltd